Back to Search Start Over

Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.

Authors :
Sinz C
Chang J
Lins AR
Brady E
Candelore M
Dallas-Yang Q
Ding V
Jiang G
Lin Z
Mock S
Qureshi S
Salituro G
Saperstein R
Shang J
Szalkowski D
Tota L
Vincent S
Wright M
Xu S
Yang X
Zhang B
Tata J
Kim R
Parmee E
Source :
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2011 Dec 01; Vol. 21 (23), pp. 7131-6. Date of Electronic Publication: 2011 Sep 29.
Publication Year :
2011

Abstract

In the course of the development of an aminobenzimidazole class of human glucagon receptor (hGCGR) antagonists, a novel class of cyclic guanidine hGCGR antagonists was discovered. Rapid N-dealkylation resulted in poor pharmacokinetic profiles for the benchmark compound in this series. A strategy aimed at blocking oxidative dealkylation led to a series of compounds with improved rodent pharmacokinetic profiles. One compound was orally efficacious in a murine glucagon challenge pharmacodynamic model and also significantly lowered glucose levels in a murine diabetes model.<br /> (Copyright © 2011 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1464-3405
Volume :
21
Issue :
23
Database :
MEDLINE
Journal :
Bioorganic & medicinal chemistry letters
Publication Type :
Academic Journal
Accession number :
22001094
Full Text :
https://doi.org/10.1016/j.bmcl.2011.09.085